NCT02925546 - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Heart Failure, Congestive

Interventions

DRUG

GSK2798745 Micronized API without SLS and hypermellose (Tablet A)

This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions

DRUG

GSK2798745 Micronized API with SLS and hypermellose (Tablet B)

This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water

DRUG

GSK2798745 milled API without SLS and hypermellose (Tablet C)

This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water

Trial Locations (1)

66211

GSK Investigational Site, Overland Park